Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations

Background In the international, phase III, randomized, double-blind CORRECT trial, regorafenib significantly prolonged overall survival (OS) versus placebo in patients with metastatic colorectal cancer (mCRC) that had progressed on all standard therapies. This post hoc analysis evaluated the effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshino, Takayuki, Komatsu, Yoshito, Yamada, Yasuhide, Yamazaki, Kentaro, Tsuji, Akihito, Ura, Takashi, Grothey, Axel, Van Cutsem, Eric, Wagner, Andrea, Cihon, Frank, Hamada, Yoko, Ohtsu, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Phase III Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4434855/
https://www.ncbi.nlm.nih.gov/pubmed/25213161
http://dx.doi.org/10.1007/s10637-014-0154-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4434855/
https://www.ncbi.nlm.nih.gov/pubmed/25213161
http://dx.doi.org/10.1007/s10637-014-0154-x

Ejemplares similares